Economic Evaluation of Andexanet Versus Prothrombin Complex Concentrate for Reversal of Factor Xa-Associated Intracranial Hemorrhage
Stroke 52:1390-1397, Micieli, A.,et al, 2021
Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared with Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation
Stroke 49:1464-1470, Reddy, V.Y.,et al, 2018
Oral Anticoagulants for Prevention of Stroke in Atrial Fibrillation: Systematic Review, Network Meta-Analysis, and Cost Effectiveness Analysis
BMJ 359:J5058, Lopez-Lopez, J.A.,et al, 2017
Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients
Stroke 47:1555-1561, Shah, A.,et al, 2016
Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
Stroke 44:1676-1681, Harringotn, A.,et al, 2013
Cost-Effectiveness of Dabigatran Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack
Stroke 43:881-883, Kamel,H.,et al, 2012
Dabigatran Etexilate versus Warfarin in Management of Non-Valvular Atrial Fibrillation in UK Context: Quantitative Benefit-Harm and Economic Analyses
BMJ 343:d6333, Pink, J.,et al, 2011
Costs and Effectiveness of Ximelagatran for Stroke Prophylaxis in Chronic Atrial Fibrillation
JAMA 293:699-706, OBrien,C.L. &Gage,B.F., 2005